Clinical trials currently enrolling participants

1. A Historical-Controlled, Multicenter, Double-Blind, Randomized, Conversion to Monotherapy Trial to Assess the Efficacy and Safety of Lacosamide (LCM) 400mg/day in Subjects with Partial-Onset Seizures (with or without secondary generalization) (SP902)
Sponsor:  Schwarz Biosciences Inc
Study agent: Lacosamide

2.  A Multicenter, Open-Label Extension Trial to Assess the Long-Term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-Onset Seizures (SP 904)
Sponsor:  Schwarz Biosciences Inc
Study agent: Lacosamide

3. Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox- Gastaut Syndrome.
Sponsor:  Ovation Pharmaceuticals
Study agent: Clobazam / Placebo

4. A Multi-Center, Double-Blind, Historical Control, Randomized Conversion to Monotherapy Study with Keppra XR for Treatment of Partial Onset Seizures.
Sponsor:  UCB Inc.
Study agent: Keppra XR/ Placebo

5. An Open-Label, Long-Term follow-up Study with Keppra XR for Treatment of Partial-Onset Seizures
Sponsor:  UCB Inc.
Study agent: Keppra XR

6. A Multicenter, Open-Label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects with Partial –Onset Seizures (SP925)
Sponsor:  Schwarz Biosciences Inc
Study agent:  Lacosamide

                                                    Active Clinical Trials

1. A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as an Add-on Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures.
Sponsor: Marinus
Study agent:  Ganaxolone / Placebo

2. An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as an Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures.
Sponsor: Marinus
Study agent:  Ganaxolone

3. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study.
Sponsor: Johnson & Johnson
Study agent:  RWJ-333369/ Placebo

4. A Double-Blind Trial Comparing the Efficacy, Tolerability, and Safety of Monotherapy Topiramate versus Phenytoin in Subjects with Seizures Indicative of New Onset Epilepsy.
Sponsor: Ortho-Mcneil
Study agent: Topiramate & Phenytoin 

5. Early Randomized Surgical Epilepsy Trial
Sponsor: NIH sub-award
Study agent: MTL/Current medicine regimen 

6. Progesterone Therapy for Women with Epilepsy
Sponsor:  NIH sub-award
Study agent: Progesterone/Placebo

7. An Open-Label Extension Trial to Determine Safety and Efficacy of Long Term Oral SPM 927 in Patients with Partial Seizures.
Sponsor: Schwarz Biosciences Inc
Study agent: SPM 927 (Lacosamide)

8. An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-Term Oral SPM 927 as Adjunctive Therapy in Patients with Partial Seizures.
Sponsor: Schwarz Biosciences Inc
Study agent: SPM 927(Lacosamide)

9. Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTÉ)
Sponsor:  Medtronic
Study agent: DBS / Placebo

10. An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 70 years old) with Partial Onset Seizures.
Sponsor:  UCB Inc.
Study agent: Brivaracetam / Placebo

11. An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam used as Adjunctive Treatment at a Flexible dose up to a Maximum of 150 mg/day in Subjects aged 16 years or older suffering from Epilepsy. 
Sponsor:  UCB Inc.
Study agent: Brivaracetam

12. Safety and Effectiveness of Open-Label Clobazam in subjects with Lennox-Gastaut Syndrome.
Sponsor:  Ovation Pharmaceuticals
Study agent: Clobazam

13. Genetic Influences on Human Epilepsy
Sponsor:  NIH sub-award

14. A Multicenter, Open-Label Extension Trial to Assess the Long-Term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects with Partial –Onset Seizures.
Sponsor:  Schwarz Biosciences Inc
Study agent:  Lacosamide